A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, And Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults with Motor Fluctuations (Tempo-3 Trial)

  • Iansek, Robert (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/62842/MH-2020
NMA SSA Reference Number: SSA/62842/MonH-2020-229611(v1)
Monash Health Reference: RES-20-0000-634X
Effective start/end date18/09/2017/09/25


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • Parkinson's disease